Tourmaline Bio, Inc.
TRML
$47.98
Updated: 23/09/2026, 22:40:19
Market Cap
$1.23B
Sector
Healthcare
Industry
Biotechnology
Country
US
Stock valuation chart
One-year closing share-price history for TRML
Company Profile
Tourmaline Bio, Inc. is a clinical-stage biotechnology firm committed to advancing therapies for individuals suffering from debilitating immune disorders. The company's development pipeline focuses on conditions such as Atherosclerotic Cardiovascular Disease (ASCVD) and Thyroid Eye Disease (TED). Established in 2021, this enterprise is headquartered in New York, New York.
USD
NASDAQ
CEO: Sandeep C. Kulkarni
Employees: 74
Asset Summaries
Latest generated summaries for TRML
No summaries found.
Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for TRML.
- Share price
- $47.98
- Market cap
- $1.23B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Sandeep C. Kulkarni
- Employees
- 74
- IPO date
- 07/05/2021
- Beta
- 1.581
- Last dividend
- $0.00
- Day range
- $47.98 – $47.98
- 52-week range
- $11.56 – $48.27
- 1-day performance
- 0.00%
- 1-year performance
- 315.05%
- Current drawdown (1Y)
- -0.60%
- CIK
- 0001827506
- CUSIP
- 89157D105
- ISIN
- US89157D1054
- Created
- 07/12/2025, 14:46:58
- Last update
- 23/09/2026, 22:40:19
Track Tourmaline Bio, Inc. with an AI analyst
See which prediction-market events move TRML, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Latest Database News
News linked to TRML from your Railway `news_articles` table.
No news found for this symbol.